Novartis Bid to Block Regeneron’s Eye Syringes to Be Probed

The U.S. International Trade Commission said it’s begun an investigation into Novartis’s request to block imports of Regeneron’s Eylea pre-filled syringes used to treat retinal diseases and made in Germany

• Novartis claims Regeneron is infringing a patent that covers syringes that will be used in its own Beovu product and is licensed to Genentech for use with Lucentis PFS for eye injections
• Dispute is over treatments for chronic eye disorders, including diabetic retinopathy, diabetic macular edema and neovascular age-related macular degeneration, which affect millions of patients each year
  • Many of the disorders are caused by too much vascular ...